H168
R(+)-7-Hydroxy-DPAT hydrobromide
>98%, solid
别名:
R(+)-2-Dipropylamino-7-hydroxy-1,2,3,4-tetrahydronaphthalene hydrobromide, R(+)-7-Hydroxy(dipropylamino)tetralin hydrobromide
登录 查看组织和合同定价。
选择尺寸
变更视图
关于此项目
经验公式（希尔记法）:
C16H25NO · HBr
化学文摘社编号:
分子量:
328.29
UNSPSC Code:
12352200
PubChem Substance ID:
MDL number:
assay
>98%
form
solid
color
white
solubility
H2O: >100 mg/mL, ethanol: >56 mg/mL
SMILES string
Br.CCCN(CCC)C1CCc2ccc(O)cc2C1
InChI
1S/C16H25NO.BrH/c1-3-9-17(10-4-2)15-7-5-13-6-8-16(18)12-14(13)11-15;/h6,8,12,15,18H,3-5,7,9-11H2,1-2H3;1H
InChI key
ODNDMTWHRYECKX-UHFFFAOYSA-N
Gene Information
human ... DRD3(1814)
Biochem/physiol Actions
Selective D3 dopamine receptor agonist; active enantiomer of (±)-7-hydroxy-DPAT.
Features and Benefits
This compound is featured on the Dopamine Receptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
Disclaimer
Photosensitive
存储类别
13 - Non Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)
法规信息
新产品
此项目有
R J Baldessarini et al.
European journal of pharmacology, 239(1-3), 269-270 (1993-08-03)
Racemic 7-hydroxy-N,N-dipropylaminotetralin (7-OH-DPAT) shows greater affinity for limbic-selective dopamine D3 receptors than for more ubiquitous dopamine D2 receptors. R(+)-7-OH-DPAT was prepared and evaluated in radioreceptor assays using membranes of fibroblasts expressing the human dopamine D3 receptor as well as rat
Susanne Koschatzky et al.
ChemMedChem, 7(3), 509-514 (2012-01-04)
The neuromodulatory peptide neurotensin has been described to functionally interact with dopaminergic pathways of the human brain. We employed radioligand binding studies to investigate the physical interaction between co-expressed dopamine D(2L) or D₃ and neurotensin NTS₁ or NTS₂ receptors. Substantial
Megan E Breuer et al.
European journal of pharmacology, 616(1-3), 134-140 (2009-06-25)
Treatment with pramipexole, a dopamine D(3)/D(2) receptor agonist, reduces depressive symptoms in patients suffering from Parkinson's disease. To test the putative antidepressant quality of pramipexole, its effects were assessed in one of the most attractive animal models of depression, the